Latest Conference Articles

The addition of belantamab mafodotin to standard-of-care VRd proved feasible as frontline therapy in newly diagnosed multiple myeloma.

Belantamab mafodotin plus lenalidomide and dexamethasone induced CRs or better in over half of patients with newly diagnosed multiple myeloma.

Administering the anti-GPRC5D agent MCARH109 and anti-BCMA therapy MCARH125 in tandem was feasible and tolerable in relapsed/refractory multiple myeloma.

Eque-cel was effective for the treatment of patients with relapsed/refractory multiple myeloma.

Arlo-cel given as a single infusion drove efficacy and was safe in relapsed/refractory multiple myeloma.

D-VRd led to favorable PRO outcomes in patients with newly diagnosed multiple myeloma who had MRD negativity after therapy.

Maintenance therapy with belantamab mafodotin, pomalidomide, and dexamethasone was safe and led to durable responses in high-risk myeloma.

Iberdomide plus daratumumab and dexamethasone yielded deep responses and had a manageable safety profile in transplant-ineligible multiple myeloma.

Data from a phase 2 study suggested that fixed-duration cevostamab is both feasible and safe in patients with heavily pretreated multiple myeloma.

Linvoseltamab plus carfilzomib produced expected toxicities in patients with heavily pretreated, relapsed/refractory multiple myeloma.

Isa-KRd led to a 74.8% MRD negativity rate in high-risk newly diagnosed multiple myeloma subgroups.

SHR-4849 showed acceptable safety and early antitumor activity in relapsed small cell lung cancer.

SHR-4849 showed acceptable safety and preliminary antitumor activity in relapsed small cell lung cancer.

ISB 2001 had a manageable safety profile and induced deep, durable responses at active doses in patients with relapsed/refractory multiple myeloma.

The combination of cevostamab, pomalidomide, and dexamethasone was deemed safe with early efficacy signals in relapsed/refractory multiple myeloma.

Early and promising efficacy was shown with elranatamab added to daratumumab/lenalidomide in transplant-ineligible, newly diagnosed multiple myeloma.

Tarlatamab plus anti–PD-L1 as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Kelsey Pan, MD, MPH, discusses notable presentations from an OncLive Fellows Forum on Thoracic Oncology.

Experts preview abstracts being presented at IMS, highlighting the role of MRD, bispecific antibodies, and other strategies to refine myeloma management.

Experts reflect on pivotal data, emerging agents, and highly anticipated trends in lung cancer during the IASLC 2025 World Conference on Lung Cancer.

Real-world data showed that lutetium Lu 177 dotatate led to partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors.

Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.

Repotrectinib elicited durable responses, including intracranial responses, in TKI-naive and -pretreated patients with NSCLC.

Five-year data show cemiplimab plus chemotherapy delivers durable OS, ORR, and DOR benefits in advanced NSCLC.

Firmonertinib was active and safe at both the 160-mg and 240-mg dose levels across a broad range of patients with NSCLC harboring EGFR PACC mutations.

Firmonertinib led to responses with a tolerable safety profile in frontline EGFR L858R–mutated NSCLC.

Tepotinib treatment was characterized by frequent but manageable TRAEs in MET exon 14–positive NSCLC, with peripheral edema as the most common toxicity.

The SKYSCRAPER-05 trial shed light on the use of perioperative tiragolumab plus atezolizumab with or without chemotherapy in NSCLC.

Tepotinib showed superior outcomes in patients with adenocarcinoma MET exon 14 skipping NSCLC vs those with non-adenocarcinoma.